NEW YORK--(BUSINESS WIRE)--May 10, 2006--OMRIX Biopharmaceuticals Inc. (NASDAQ: OMRI - News), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, today reported financial and operating results for the first quarter of 2006. Today’s announcement represents OMRIX’s first financial report since it became a public company on April 21, 2006, raising approximately $40 million, including the exercise of the over-allotment option, or about $35 million, net of commissions and expenses.
